NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fireside Chat at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition ...
The Dividend Income Accelerator Portfolio delivers a 3.98% yield and 7.11% five-year dividend growth, balancing income and growth for strong risk-adjusted returns. Our portfolio is globally diversified, with reduced company and sector concentration risk, enhancing stability and lowering overall risk. Large-cap, value-focused holdings dominate, further reducing risk and supporting consistent div...
A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid ...
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last week.
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies , including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites Submission underscores potential to shift the treatment paradi...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.